An inhibition enzyme immunoassay (IEIA), using a human monoclonal antibody (K14) reactive with gp41 of HIV-1, was evaluated for its applicability to the serology of HIV-1 infections. Using panels of serum samples from seronegative and confirmed HIV-1-seropositive individuals, it was shown that all the HIV-1-positive samples in a panel from The Netherlands and 97% of the HIV-1-positive samples from Tanzania were identified by this IEIA. Six per cent of the IEIA-positive samples from Tanzania could not be confirmed in other assays. Testing of serial dilutions of serum samples from African individuals with confirmed HIV-1, HIV-2 or HIV(ANI70) infections in the K14 IEIA, indicated that a HIV-1-specific assay based on this principle may be developed.

*Immunoenzyme Techniques, 0 (Antibodies, Monoclonal), 0 (HIV Envelope Protein gp41), Antibodies, Monoclonal/*immunology, Evaluation Studies, HIV Envelope Protein gp41/*immunology, HIV Infections/*diagnosis, HIV-1/*immunology, Human, Support, Non-U.S. Gov't
Erasmus MC: University Medical Center Rotterdam

Teeuwsen, V.J.P, Schalken, J.J, van der Groen, G, van den Akker, R, Goudsmit, J, & Osterhaus, A.D.M.E. (1991). An inhibition enzyme immunoassay, using a human monoclonal antibody (K14) reactive with gp41 of HIV-1, for the serology of HIV-1 infections. AIDS, 5(7), 893–896. Retrieved from